{
    "ticker": "NTLA",
    "name": "Intellia Therapeutics, Inc.",
    "description": "Intellia Therapeutics, Inc. is a leading biotechnology company focused on developing transformative gene-editing therapies using its proprietary CRISPR/Cas9 technology. Founded in 2014 and headquartered in Cambridge, Massachusetts, Intellia is at the forefront of the genomic medicine revolution. The company's mission is to harness the power of CRISPR to create curative treatments for genetic diseases, with a focus on both in vivo and ex vivo applications. Intellia's innovative approach allows for precise editing of genes, which has the potential to treat a wide range of diseases, including rare genetic disorders and common diseases like cancer. The company has multiple clinical programs, including those targeting transthyretin amyloidosis (ATTR) and various hematological diseases. Their lead candidate, NTLA-2001, is being evaluated in clinical trials for its efficacy and safety in treating ATTR. Intellia collaborates with other leading organizations and academic institutions to advance its research and broaden the potential applications of its technology. As the gene-editing landscape evolves, Intellia aims to pioneer new therapies that can offer patients hope for previously untreatable conditions, thereby making significant contributions to the field of medicine and improving patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2014",
    "website": "https://www.intelliatx.com",
    "ceo": "John Leonard",
    "social_media": {
        "twitter": "https://twitter.com/intelliatx",
        "linkedin": "https://www.linkedin.com/company/intellia-therapeutics"
    },
    "investor_relations": "https://investors.intelliatx.com",
    "key_executives": [
        {
            "name": "John Leonard",
            "position": "CEO"
        },
        {
            "name": "Andrew P. Wilkerson",
            "position": "CFO",
            "social_media": {
                "linkedin": "https://www.linkedin.com/in/andrewwilkerson"
            }
        }
    ],
    "product_categories": [
        {
            "category": "Gene Editing Therapies",
            "products": [
                "NTLA-2001",
                "NTLA-3001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Intellia Therapeutics, Inc. | Pioneering Gene Editing Solutions",
        "meta_description": "Explore Intellia Therapeutics, Inc., a biotechnology leader focused on gene editing therapies using CRISPR technology. Learn about their innovative treatments and commitment to advancing medicine.",
        "keywords": [
            "Intellia",
            "Gene Editing",
            "CRISPR",
            "Biotechnology",
            "Pharmaceuticals",
            "NTLA-2001",
            "Genetic Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Intellia Therapeutics known for?",
            "answer": "Intellia Therapeutics is known for developing gene-editing therapies using CRISPR technology."
        },
        {
            "question": "Who is the CEO of Intellia Therapeutics?",
            "answer": "John Leonard is the CEO of Intellia Therapeutics, Inc."
        },
        {
            "question": "Where is Intellia headquartered?",
            "answer": "Intellia is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Intellia's main products?",
            "answer": "Intellia's main products include NTLA-2001 and NTLA-3001, which are gene-editing therapies."
        },
        {
            "question": "When was Intellia founded?",
            "answer": "Intellia was founded in 2014."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMY"
    ]
}